CJC-1295 With DAC

GHRH analog peptide with Drug Affinity Complex

CJC-1295 With DAC is classified as a growth-hormone-releasing hormone (GHRH) analog peptide carrying a Drug Affinity Complex (DAC) modification. The DAC group is associated with an extended half-life relative to the non-DAC variant in the literature. This page is background about the molecule as a research material and is not medical guidance and not intended for human or animal use.

Classification and structure

CJC-1295 With DAC is a modified GHRH(1-29) analog to which a Drug Affinity Complex has been conjugated. The DAC moiety is designed to bind circulating albumin, a feature described in the literature as prolonging the peptide's presence relative to unmodified GHRH analogs. It is classified as a long-acting GHRH-receptor-directed analog for research purposes.

Areas of research

In the scientific literature this peptide appears across the following research areas.

• Half-life extension research — Investigated as a model for albumin-binding strategies that extend peptide circulation time.
• GHRH-receptor research — Appears in laboratory studies of GHRH-receptor interaction within the somatotropic axis.
• Peptide analog design — Featured in work comparing DAC-modified and unmodified GHRH analogs.

As always in this library, describing a compound as “studied in” an area is a statement about where scientific attention has gone — not a claim that it produces any result in humans or animals.

Handling and verification

Store lyophilized peptide cold and protected from light per standard peptide handling practice. Every in-stock lot ships with a verifiable third-party certificate of analysis (COA).